CDKN2A L16P

CI-VAR-00002274Explore in graph →CIViC 3335

Curated evidence

Evidence by cancer (2 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–2 of 2 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Unmapped disease2unmapped disease
CDKN2A L16P	(functional)	Functional	D	Supports Loss Of Function	3	submitted	EID9321 Analysis of several CDKN2A variants was performed to discover their functional impact. An in vitro binding assay found that CDKN2A L16P resulted in decreased binding to CDK4 and CDK6. Protein structur… (full text at CIViC) PMID 10498896 · Ruas et al., 1999 · Open in CIViC	civic
CDKN2A L16P	(functional)	Functional	D	Supports Loss Of Function	3	rejected	EID9322 Analysis of several CDKN2A variants was performed to discover their functional impact. An in vitro binding assay found that CDKN2A L16P resulted in decreased binding to CDK4 and CDK6. Protein structur… (full text at CIViC) PMID 10498896 · Ruas et al., 1999 · Open in CIViC	civic

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.